You are here

Publications

Search

Show only items where

Author

Type

Term

Year

Keyword

Found 2724 results

Filters: First Letter Of Last Name is S [Clear All Filters]

2025

Nguyen, B. V., Özden, C., Dong, K., Koc, O. Can, Torres-Ocampo, A. P., Dziedzic, N., Flaherty, D., Huang, J., Sankara, S., Abromson, N. Lyn, Tomchick, D. R., Fissore, R. A., Chen, J., Garman, S. C., and Stratton, M. M. (2025) A domain-swapped CaMKII conformation facilitates linker-mediated allosteric regulation. Nat Commun. 16, 8461

Pallapati, A. R., Korkmaz, F., Rojekar, S., Sims, S., Misra, A., Gimenez-Roig, J., Gangadhar, A., Laurencin, V., Gumerova, A., Cheliadinova, U., Sultana, F., Vasilyeva, D., Cullen, L., Schuermann, J., Munitz, J., Kannangara, H., Parte, S., Pevnev, G., Burganova, G., Tumoglu, Z., Witztum, R., Wizman, S., Kramskiy, N., Igel, L., Sen, F., Ranzenigo, A., Macdonald, A., Hutchison, S., Teunissen, A. Jp, Burkart, H., Saxena, M., Ginzburg, Y., Goosens, K., Zhou, W., Ryu, V., Moldavski, O., Barak, O., Pazianas, M., Caminis, J., Bhasin, S., Fitzgerald, R., Kim, S. - M., Quinn, M., Haider, S., Appt, S., Frolinger, T., Rosen, C. J., Lizneva, D., Gupta, Y. K., Yuen, T., and Zaidi, M. (2025) Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer's disease models. J Clin Invest. 10.1172/JCI182702

Pallapati, A. R., Korkmaz, F., Rojekar, S., Sims, S., Misra, A., Gimenez-Roig, J., Gangadhar, A., Laurencin, V., Gumerova, A., Cheliadinova, U., Sultana, F., Vasilyeva, D., Cullen, L., Schuermann, J., Munitz, J., Kannangara, H., Parte, S., Pevnev, G., Burganova, G., Tumoglu, Z., Witztum, R., Wizman, S., Kramskiy, N., Igel, L., Sen, F., Ranzenigo, A., Macdonald, A., Hutchison, S., Teunissen, A. Jp, Burkart, H., Saxena, M., Ginzburg, Y., Goosens, K., Zhou, W., Ryu, V., Moldavski, O., Barak, O., Pazianas, M., Caminis, J., Bhasin, S., Fitzgerald, R., Kim, S. - M., Quinn, M., Haider, S., Appt, S., Frolinger, T., Rosen, C. J., Lizneva, D., Gupta, Y. K., Yuen, T., and Zaidi, M. (2025) Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer's disease models. J Clin Invest. 10.1172/JCI182702

Pallapati, A. R., Korkmaz, F., Rojekar, S., Sims, S., Misra, A., Gimenez-Roig, J., Gangadhar, A., Laurencin, V., Gumerova, A., Cheliadinova, U., Sultana, F., Vasilyeva, D., Cullen, L., Schuermann, J., Munitz, J., Kannangara, H., Parte, S., Pevnev, G., Burganova, G., Tumoglu, Z., Witztum, R., Wizman, S., Kramskiy, N., Igel, L., Sen, F., Ranzenigo, A., Macdonald, A., Hutchison, S., Teunissen, A. Jp, Burkart, H., Saxena, M., Ginzburg, Y., Goosens, K., Zhou, W., Ryu, V., Moldavski, O., Barak, O., Pazianas, M., Caminis, J., Bhasin, S., Fitzgerald, R., Kim, S. - M., Quinn, M., Haider, S., Appt, S., Frolinger, T., Rosen, C. J., Lizneva, D., Gupta, Y. K., Yuen, T., and Zaidi, M. (2025) Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer's disease models. J Clin Invest. 10.1172/JCI182702

Pallapati, A. R., Korkmaz, F., Rojekar, S., Sims, S., Misra, A., Gimenez-Roig, J., Gangadhar, A., Laurencin, V., Gumerova, A., Cheliadinova, U., Sultana, F., Vasilyeva, D., Cullen, L., Schuermann, J., Munitz, J., Kannangara, H., Parte, S., Pevnev, G., Burganova, G., Tumoglu, Z., Witztum, R., Wizman, S., Kramskiy, N., Igel, L., Sen, F., Ranzenigo, A., Macdonald, A., Hutchison, S., Teunissen, A. Jp, Burkart, H., Saxena, M., Ginzburg, Y., Goosens, K., Zhou, W., Ryu, V., Moldavski, O., Barak, O., Pazianas, M., Caminis, J., Bhasin, S., Fitzgerald, R., Kim, S. - M., Quinn, M., Haider, S., Appt, S., Frolinger, T., Rosen, C. J., Lizneva, D., Gupta, Y. K., Yuen, T., and Zaidi, M. (2025) Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer's disease models. J Clin Invest. 10.1172/JCI182702

Pallapati, A. R., Korkmaz, F., Rojekar, S., Sims, S., Misra, A., Gimenez-Roig, J., Gangadhar, A., Laurencin, V., Gumerova, A., Cheliadinova, U., Sultana, F., Vasilyeva, D., Cullen, L., Schuermann, J., Munitz, J., Kannangara, H., Parte, S., Pevnev, G., Burganova, G., Tumoglu, Z., Witztum, R., Wizman, S., Kramskiy, N., Igel, L., Sen, F., Ranzenigo, A., Macdonald, A., Hutchison, S., Teunissen, A. Jp, Burkart, H., Saxena, M., Ginzburg, Y., Goosens, K., Zhou, W., Ryu, V., Moldavski, O., Barak, O., Pazianas, M., Caminis, J., Bhasin, S., Fitzgerald, R., Kim, S. - M., Quinn, M., Haider, S., Appt, S., Frolinger, T., Rosen, C. J., Lizneva, D., Gupta, Y. K., Yuen, T., and Zaidi, M. (2025) Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer's disease models. J Clin Invest. 10.1172/JCI182702

Slezak, T., O'Leary, K. M., Li, J., Rohaim, A., Davydova, E. K., and Kossiakoff, A. A. (2025) Engineered protein G variants for multifunctional antibody-based assemblies. Protein Sci. 34, e70019

Ota, N., Davies, C. W., Kang, J., Yan, D., Scherl, A., Wong, A., Cook, R., Tao, X., Dunlap, D., Klabunde, S., Mantik, P., Mohanan, V., Lin, W. Y., McBride, J., Sadekar, S., Storek, K. M., Lupardus, P., Ye, Z., Wallweber, H. Ackerly, Kiefer, J. R., Xu, M., Chan, P., Nagapudi, K., Yi, T., and Koerber, J. T. (2025) Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling. Proc Natl Acad Sci U S A. 122, e2501635122

Ota, N., Davies, C. W., Kang, J., Yan, D., Scherl, A., Wong, A., Cook, R., Tao, X., Dunlap, D., Klabunde, S., Mantik, P., Mohanan, V., Lin, W. Y., McBride, J., Sadekar, S., Storek, K. M., Lupardus, P., Ye, Z., Wallweber, H. Ackerly, Kiefer, J. R., Xu, M., Chan, P., Nagapudi, K., Yi, T., and Koerber, J. T. (2025) Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling. Proc Natl Acad Sci U S A. 122, e2501635122

Ota, N., Davies, C. W., Kang, J., Yan, D., Scherl, A., Wong, A., Cook, R., Tao, X., Dunlap, D., Klabunde, S., Mantik, P., Mohanan, V., Lin, W. Y., McBride, J., Sadekar, S., Storek, K. M., Lupardus, P., Ye, Z., Wallweber, H. Ackerly, Kiefer, J. R., Xu, M., Chan, P., Nagapudi, K., Yi, T., and Koerber, J. T. (2025) Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling. Proc Natl Acad Sci U S A. 122, e2501635122

Hemmings, M., Zieliński, M., Golkar, T., Blanchet, J., Pistofidis, A., Munro, K., T Schmeing, M., D Bohle, S., and Berghuis, A. M. (2025) Enzyme-mediated aminoglycoside resistance without target mimicry. Commun Chem. 8, 258

Słabicki, M., Park, J., Nowak, R. P., Burman, S. S. Roy, Pellman, J., Zou, C., Razumkov, H., Carreiro, J., Rastogi, S., Goldstein, A., Nagiec, M. M., Donovan, K. A., Che, J., Hunkeler, M., Geng, Q., Hsu, C. - L., Lakshminarayan, M., Shu, C., Zon, R. L., Kozicka, Z., Park, P. M. C., Tsai, J. M., Yoon, H., Jones, L. H., Sperling, A. S., Gray, N. S., Fischer, E. S., and Ebert, B. L. (2025) Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation. Mol Cell. 85, 3184-3201.e14

Słabicki, M., Park, J., Nowak, R. P., Burman, S. S. Roy, Pellman, J., Zou, C., Razumkov, H., Carreiro, J., Rastogi, S., Goldstein, A., Nagiec, M. M., Donovan, K. A., Che, J., Hunkeler, M., Geng, Q., Hsu, C. - L., Lakshminarayan, M., Shu, C., Zon, R. L., Kozicka, Z., Park, P. M. C., Tsai, J. M., Yoon, H., Jones, L. H., Sperling, A. S., Gray, N. S., Fischer, E. S., and Ebert, B. L. (2025) Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation. Mol Cell. 85, 3184-3201.e14

Słabicki, M., Park, J., Nowak, R. P., Burman, S. S. Roy, Pellman, J., Zou, C., Razumkov, H., Carreiro, J., Rastogi, S., Goldstein, A., Nagiec, M. M., Donovan, K. A., Che, J., Hunkeler, M., Geng, Q., Hsu, C. - L., Lakshminarayan, M., Shu, C., Zon, R. L., Kozicka, Z., Park, P. M. C., Tsai, J. M., Yoon, H., Jones, L. H., Sperling, A. S., Gray, N. S., Fischer, E. S., and Ebert, B. L. (2025) Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation. Mol Cell. 85, 3184-3201.e14

Stopper, D., Biermann, L., Watson, P. R., Li, J., König, B., Gaynes, M. N., de Carvalho, L. Pessanha, Klose, J., Hanl, M., Hamacher, A., Schäker-Hübner, L., Ramsbeck, D., Held, J., Christianson, D. W., Kassack, M. U., and Hansen, F. K. (2025) Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties. J Med Chem. 10.1021/acs.jmedchem.4c02373

Stopper, D., Biermann, L., Watson, P. R., Li, J., König, B., Gaynes, M. N., de Carvalho, L. Pessanha, Klose, J., Hanl, M., Hamacher, A., Schäker-Hübner, L., Ramsbeck, D., Held, J., Christianson, D. W., Kassack, M. U., and Hansen, F. K. (2025) Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties. J Med Chem. 10.1021/acs.jmedchem.4c02373

Dussupt, V., Jensen, J. L., Thomas, P. V., Mendez-Rivera, L., Lal, K. G., McCrea, M. Zemil, Swafford, I., Hernandez, J., Sankhala, R. S., Rao, M., Arora, J., Hajduczki, A., Jian, N., Rees, P. A., De Leon, I. Showell-, Smith, G., Smith, L., Wasson, D., Schmid, A., Teng, I. - T., Zhou, T., Kwong, P. D., Currier, J. R., Reiley, W. W., Paquin-Proulx, D., Polonis, V. R., Collins, N. D., Michael, N. L., M Joyce, G., and Krebs, S. J. (2025) First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challenge. mBio. 16, e0103625

Dussupt, V., Jensen, J. L., Thomas, P. V., Mendez-Rivera, L., Lal, K. G., McCrea, M. Zemil, Swafford, I., Hernandez, J., Sankhala, R. S., Rao, M., Arora, J., Hajduczki, A., Jian, N., Rees, P. A., De Leon, I. Showell-, Smith, G., Smith, L., Wasson, D., Schmid, A., Teng, I. - T., Zhou, T., Kwong, P. D., Currier, J. R., Reiley, W. W., Paquin-Proulx, D., Polonis, V. R., Collins, N. D., Michael, N. L., M Joyce, G., and Krebs, S. J. (2025) First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challenge. mBio. 16, e0103625

Dussupt, V., Jensen, J. L., Thomas, P. V., Mendez-Rivera, L., Lal, K. G., McCrea, M. Zemil, Swafford, I., Hernandez, J., Sankhala, R. S., Rao, M., Arora, J., Hajduczki, A., Jian, N., Rees, P. A., De Leon, I. Showell-, Smith, G., Smith, L., Wasson, D., Schmid, A., Teng, I. - T., Zhou, T., Kwong, P. D., Currier, J. R., Reiley, W. W., Paquin-Proulx, D., Polonis, V. R., Collins, N. D., Michael, N. L., M Joyce, G., and Krebs, S. J. (2025) First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challenge. mBio. 16, e0103625

Dussupt, V., Jensen, J. L., Thomas, P. V., Mendez-Rivera, L., Lal, K. G., McCrea, M. Zemil, Swafford, I., Hernandez, J., Sankhala, R. S., Rao, M., Arora, J., Hajduczki, A., Jian, N., Rees, P. A., De Leon, I. Showell-, Smith, G., Smith, L., Wasson, D., Schmid, A., Teng, I. - T., Zhou, T., Kwong, P. D., Currier, J. R., Reiley, W. W., Paquin-Proulx, D., Polonis, V. R., Collins, N. D., Michael, N. L., M Joyce, G., and Krebs, S. J. (2025) First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challenge. mBio. 16, e0103625

Dussupt, V., Jensen, J. L., Thomas, P. V., Mendez-Rivera, L., Lal, K. G., McCrea, M. Zemil, Swafford, I., Hernandez, J., Sankhala, R. S., Rao, M., Arora, J., Hajduczki, A., Jian, N., Rees, P. A., De Leon, I. Showell-, Smith, G., Smith, L., Wasson, D., Schmid, A., Teng, I. - T., Zhou, T., Kwong, P. D., Currier, J. R., Reiley, W. W., Paquin-Proulx, D., Polonis, V. R., Collins, N. D., Michael, N. L., M Joyce, G., and Krebs, S. J. (2025) First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challenge. mBio. 16, e0103625

Hazari, A., Sawaya, M. R., Lee, H., Sajimon, M., Kim, H., Iii, W. A. Goddard, Eisenberg, D., and Raskatov, J. A. (2025) Formation of rippled β-sheets from mixed chirality linear and cyclic peptides-new structural motifs based on the pauling-corey rippled β-sheet.. Chem Sci. 16, 5907-5917

Hazari, A., Sawaya, M. R., Lee, H., Sajimon, M., Kim, H., Iii, W. A. Goddard, Eisenberg, D., and Raskatov, J. A. (2025) Formation of rippled β-sheets from mixed chirality linear and cyclic peptides-new structural motifs based on the pauling-corey rippled β-sheet.. Chem Sci. 16, 5907-5917

Andree, G. A., Miller-Brown, K. R., Zhao, Z., Smith, A. K., Dawson, C. D., Deredge, D. J., and Drennan, C. L. (2025) How ATP and dATP reposition class III ribonucleotide reductase cone domains to regulate enzyme activity. Sci Adv. 11, eady9156

Streeter, O., Shi, K., Vavra, J., Aihara, H., Ervasti, J. M., Evans, R., and Muretta, J. M. (2025) Human dystrophin tandem calponin homology actin-binding domain crystallized in a closed-state conformation. Acta Crystallogr D Struct Biol. 81, 122-129

Pages

Quick Links

The Northeastern Collaborative Access Team (NE-CAT) facility at the Advanced Photon Source at Argonne National Laboratory is managed by Cornell University and consists of eight member institutions:

Columbia University
Cornell University
Genentech
Harvard University
Massachusetts Institute of Technology
Memorial Sloan-Kettering Cancer Center
Rockefeller University
Yale University

Primary funding for this project comes from the National Institute of General Medical Sciences (NIGMS), a division of the National Institutes of Health (NIH). Additional financial support for NE-CAT comes from the member institutions.